About pegcetacoplan
Complement inhibitor
Used for
- Treats paroxysmal nocturnal hemoglobinuria (PNH) in adults.
- Treats C3 glomerulopathy in adults and children weighing at least 30 kg.
Usual adult dose
PNH: 1,080 mg under the skin twice weekly. C3 glomerulopathy: 1,080 mg twice weekly; dosing may vary by weight or response.
Usual dose in children
C3 glomerulopathy, age 12 years or older and weight at least 30 kg: 1,080 mg twice weekly; dosing may vary by weight or response. Not established for PNH in children.
Common side effects
- Injection-site reactions
- Upper respiratory infections
- Diarrhea or abdominal pain
- Headache
Important warnings
- Can increase risk of serious infections, including meningococcal, pneumococcal, and Haemophilus influenzae infections.
- Vaccinations against these bacteria are required before treatment when possible; urgent antibiotics may be needed if treatment starts sooner.
- Seek urgent care for fever, severe headache, stiff neck, confusion, or other signs of serious infection.
- Do not stop treatment without medical supervision; PNH symptoms or hemolysis may return.
Pregnancy
Human pregnancy data are limited. Use only when potential benefit justifies potential risk; disease control and risks of untreated PNH or C3 glomerulopathy matter.
Breastfeeding
It is unknown whether pegcetacoplan passes into breast milk. Consider treatment benefits and potential infant risks with a clinician.
Interactions
- No major drug interactions are established; tell clinicians about all medicines and vaccines.
- Live vaccines may pose infection risks during treatment.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.